Skip to main content
Premium Trial:

Request an Annual Quote

Agendia Registers MammaPrint Microarray Test With Dutch Gov t

NEW YORK, Nov. 1 (GenomeWeb News) - Agendia has registered its MammaPrint microarray test as a medical device with the Dutch Healthcare Inspectorate, the company said today. Both the microarray and the array production were registered.

 

Agendia said the registration complies with Dutch law on medical devices and enables MammaPrint to bear the CE mark. Agendia recently received accreditation for MammaPrint.

 

The MammaPrint gene-expression service assesses the risk of metastasis in breast cancer patients with a 70-gene profile.

 

The Amsterdam, Netherlands-based company will also register its other genetic profile-based tests, such as CupPrint, a test for cancer of unknown primary patients.

The Scan

Dropped Charges

The US Justice Department has dropped visa fraud charges against five Chinese researchers, according to the Wall Street Journal.

More Kids

The Associated Press says Moderna is expanding its SARS-CoV-2 vaccine study to included additional children and may include even younger children.

PNAS Papers on Rat Clues to Human Migration, Thyroid Cancer, PolyG-DS

In PNAS this week: ancient rat genome analysis gives hints to human migrations, WDR77 gene mutations in thyroid cancer, and more.

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.